Di Zhe Pharmaceuticals Reports Revenue Surpassing $500 Million in First Half, Advances Globalization Strategy into Innovation Value Realization Phase

Di Zhe Pharmaceuticals (stock code: 688192.SH) announced its 2026 interim report on August 20, 2026, revealing a revenue of $523 million during the reporting period, marking a 47% increase from the same period last year. The strong financial performance of Di Zhe Pharmaceuticals in the first half of 2026 showcases the company’s robust growth trajectory, with a significant uptick in revenue to over $500 million. This growth momentum underscores the successful execution of the company’s global expansion strategy, propelling it into a phase focused on capitalizing on innovative value. With a notable revenue increase of 47% compared to the previous…